T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents

[1]  A. Copas,et al.  Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study , 2022, The Lancet Healthy Longevity.

[2]  P. Rieu,et al.  Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2– Recovered Dialysis Patients , 2022, Clinical journal of the American Society of Nephrology : CJASN.

[3]  G. Onder,et al.  A Third Dose of mRNA COVID-19 Vaccine Significantly Enhances Anti–SARS-CoV-2 Spike IgG Response in Nursing Home Residents in Italy , 2022, Journal of the American Medical Directors Association.

[4]  A. Benetos,et al.  Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents , 2022, Journal of the American Geriatrics Society.

[5]  E. Albert,et al.  SARS-CoV-2 adaptive immunity in nursing home residents following a third dose of the Comirnaty® COVID-19 vaccine , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  B. Ramos,et al.  Humoral and Cellular Response after mRNA Vaccination in Nursing Homes: Influence of Age and of History of COVID-19 , 2022, Vaccines.

[7]  M. Picot,et al.  Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents , 2022, Journal of the American Medical Directors Association.

[8]  G. Onder,et al.  Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study , 2022, Vaccine.

[9]  G. Brady,et al.  Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents , 2022, Journal of the American Medical Directors Association.

[10]  Bärbel Camara,et al.  Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults , 2021, Nature Microbiology.

[11]  V. Lauschke,et al.  Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID‐A Study , 2021, Journal of the American Geriatrics Society.

[12]  A. Duhamel,et al.  Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People , 2021, Frontiers in Immunology.

[13]  M. Stiffel,et al.  COVID-19 in long-term care , 2021, OECD Health Working Papers.

[14]  V. Ippolito,et al.  Clinical Features of SARS-CoV-2 Infection in Italian Long-Term Care Facilities: GeroCovid LTCFs Observational Study , 2021, Journal of the American Medical Directors Association.

[15]  H. Ikematsu,et al.  Contrasting specific antibody response to BNT162b2 mRNA vaccination in SARS-CoV-2-naive and previously infected nursing home residents , 2021, Journal of Infection.

[16]  Frances E. Muldoon,et al.  Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 , 2021, Nature.

[17]  E. Albert,et al.  B- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents , 2021, Clinical Microbiology and Infection.

[18]  M. Cameron,et al.  Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Naive Nursing Home Residents , 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[19]  M. Picot,et al.  Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort‐19 study , 2021, Allergy.

[20]  G. Onder,et al.  Proceedings from an International Virtual Townhall: Reflecting on the COVID-19 Pandemic: Themes from Long-Term Care , 2021, Journal of the American Medical Directors Association.

[21]  G. Pawelec,et al.  Unanticipated efficacy of SARS-CoV-2 vaccination in older adults , 2021, Immunity & ageing : I & A.

[22]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[23]  L. Ferrucci,et al.  The conundrum of human immune system “senescence” , 2020, Mechanisms of Ageing and Development.

[24]  S. Sinha,et al.  A Comparison of COVID-19 Mortality Rates Among Long-Term Care Residents in 12 OECD Countries , 2020, Journal of the American Medical Directors Association.

[25]  M. Kivipelto,et al.  Age, Frailty, and Comorbidity as Prognostic Factors for Short-Term Outcomes in Patients With Coronavirus Disease 2019 in Geriatric Care , 2020, Journal of the American Medical Directors Association.

[26]  I. Bogoch,et al.  Risk Factors Associated With Mortality Among Residents With Coronavirus Disease 2019 (COVID-19) in Long-term Care Facilities in Ontario, Canada , 2020, JAMA network open.

[27]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[28]  G. Onder,et al.  Clinical Characteristics of Hospitalized Individuals Dying with COVID-19 by Age Group in Italy , 2020, The journals of gerontology. Series A, Biological sciences and medical sciences.

[29]  D. Sinclair,et al.  Why does COVID-19 disproportionately affect older people? , 2020, Aging.